GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » GeneTether Therapeutics Inc (XCNQ:GTTX) » Definitions » Total Liabilities

GeneTether Therapeutics (XCNQ:GTTX) Total Liabilities : C$0.03 Mil (As of Jun. 2024)


View and export this data going back to 2022. Start your Free Trial

What is GeneTether Therapeutics Total Liabilities?

GeneTether Therapeutics's Total Liabilities for the quarter that ended in Jun. 2024 was C$0.03 Mil.

GeneTether Therapeutics's quarterly Total Liabilities increased from Dec. 2023 (C$0.05 Mil) to Mar. 2024 (C$0.07 Mil) but then declined from Mar. 2024 (C$0.07 Mil) to Jun. 2024 (C$0.03 Mil).

GeneTether Therapeutics's annual Total Liabilities declined from Dec. 2021 (C$0.27 Mil) to Dec. 2022 (C$0.12 Mil) and declined from Dec. 2022 (C$0.12 Mil) to Dec. 2023 (C$0.05 Mil).


GeneTether Therapeutics Total Liabilities Historical Data

The historical data trend for GeneTether Therapeutics's Total Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

GeneTether Therapeutics Total Liabilities Chart

GeneTether Therapeutics Annual Data
Trend Dec20 Dec21 Dec22 Dec23
Total Liabilities
0.16 0.27 0.12 0.05

GeneTether Therapeutics Quarterly Data
Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24
Total Liabilities Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.05 0.04 0.05 0.07 0.03

GeneTether Therapeutics Total Liabilities Calculation

Total Liabilities are the liabilities that the company has to pay others. It is a part of the balance sheet of a company that shareholders do not own, and would be obligated to pay back if the company liquidated.

GeneTether Therapeutics's Total Liabilities for the fiscal year that ended in Dec. 2023 is calculated as

Total Liabilities=Total Current Liabilities+Total Noncurrent Liabilities
=Total Current Liabilities+(Long-Term Debt & Capital Lease Obligation+Other Long-Term Liabilities
=0.052+(0+0
+NonCurrent Deferred Liabilities+PensionAndRetirementBenefit)
+0+0)
=0.05

Total Liabilities=Total Assets (A: Dec. 2023 )-Total Equity (A: Dec. 2023 )
=1.893-1.841
=0.05

GeneTether Therapeutics's Total Liabilities for the quarter that ended in Jun. 2024 is calculated as

Total Liabilities=Total Current Liabilities+Total Noncurrent Liabilities
=Total Current Liabilities+(Long-Term Debt & Capital Lease Obligation+Other Long-Term Liabilities
=0.032+(0+0
+NonCurrent Deferred Liabilities+PensionAndRetirementBenefit)
+0+0)
=0.03

Total Liabilities=Total Assets (Q: Jun. 2024 )-Total Equity (Q: Jun. 2024 )
=1.513-1.482
=0.03

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


GeneTether Therapeutics Total Liabilities Related Terms

Thank you for viewing the detailed overview of GeneTether Therapeutics's Total Liabilities provided by GuruFocus.com. Please click on the following links to see related term pages.


GeneTether Therapeutics Business Description

Traded in Other Exchanges
N/A
Address
301-1665 Ellis Street, c/o Pushor Mitchell LLP, Kelowna, BC, CAN, X1X 1X1
GeneTether Therapeutics Inc is a genetic medicines company focused on the development of high-efficiency precision gene editing for human therapeutics applications. It is engaged in creating gene-editing therapies based on the proprietary GeneTether platform. Further, it is focused on building a discovery pipeline for the treatment of rare, monogenic diseases of the kidney and the skin. Their platform is designed to increase the efficiency of genome editing technologies, including CRISPR-Cas, TALENs, and ZFNs.

GeneTether Therapeutics Headlines

No Headlines